Home » Medtronic Announces FDA Approval to Enroll First U.S. Renal Denervation Clinical Study
Medtronic Announces FDA Approval to Enroll First U.S. Renal Denervation Clinical Study
The FDA has approved an investigational device exemption allowing Medtronic to initiate Symplicity HTN-4, the first randomized trial to investigate renal denervation for the treatment of moderate uncontrolled hypertension in U.S. patients.
MarketWatch
MarketWatch
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May